98 related articles for article (PubMed ID: 12123658)
1. Quantitation of gene-specific DNA damage by competitive PCR.
Fernando LP; Kurian PJ; Fidan M; Fernandes DJ
Anal Biochem; 2002 Jul; 306(2):212-21. PubMed ID: 12123658
[TBL] [Abstract][Full Text] [Related]
2. Arrest of replication fork progression at sites of topoisomerase II-mediated DNA cleavage in human leukemia CEM cells incubated with VM-26.
Catapano CV; Carbone GM; Pisani F; Qiu J; Fernandes DJ
Biochemistry; 1997 May; 36(19):5739-48. PubMed ID: 9153414
[TBL] [Abstract][Full Text] [Related]
3. Detection of DNA damage in transcriptionally active genes by RT-PCR and assessment of repair of cisplatin-induced damage in the glutathione S-transferase-pi gene in human glioblastoma cells.
Brandt TY; Ali-Osman F
Toxicol Appl Pharmacol; 1997 Mar; 143(1):22-9. PubMed ID: 9073588
[TBL] [Abstract][Full Text] [Related]
4. Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells.
Morgan SE; Kim R; Wang PC; Bhat UG; Kusumoto H; Lu T; Beck WT
Oncogene; 2000 Oct; 19(43):5010-9. PubMed ID: 11042688
[TBL] [Abstract][Full Text] [Related]
5. Dissociation between bulk damage to DNA and the antiproliferative activity of teniposide (VM-26) in the MCF-7 breast tumor cell line: evidence for induction of gene-specific damage and alterations in gene expression.
Gewirtz DA; Orr MS; Fornari FA; Randolph JK; Yalowich JC; Ritke MK; Povirk LF; Bunch RT
Cancer Res; 1993 Aug; 53(15):3547-54. PubMed ID: 8339261
[TBL] [Abstract][Full Text] [Related]
6. Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression.
Bertrand R; Sarang M; Jenkin J; Kerrigan D; Pommier Y
Cancer Res; 1991 Dec; 51(23 Pt 1):6280-5. PubMed ID: 1933888
[TBL] [Abstract][Full Text] [Related]
7. Polymerase chain reaction analysis of cisplatin-induced mitochondrial DNA damage in human ovarian carcinoma cells.
Daoud SS; Clements MK; Small CL
Anticancer Drugs; 1995 Jun; 6(3):405-12. PubMed ID: 7670138
[TBL] [Abstract][Full Text] [Related]
8. Gene-specific damage produced by cisplatin, ormaplatin and UV light in human cells as assayed by the polymerase chain reaction.
Oshita F; Eastman A
Oncol Res; 1993; 5(3):111-8. PubMed ID: 8260747
[TBL] [Abstract][Full Text] [Related]
9. Suppression of c-myc expression and c-Myc function in response to sustained DNA damage in MCF-7 breast tumor cells.
Magnet KJ; Orr MS; Cleveland JL; Rodriguez-Galindo C; Yang H; Yang C; Di YM; Jain PT; Gewirtz DA
Biochem Pharmacol; 2001 Sep; 62(5):593-602. PubMed ID: 11585056
[TBL] [Abstract][Full Text] [Related]
10. Quantitation of c-myc gene amplification by a competitive PCR assay system.
Harlow SP; Stewart CC
PCR Methods Appl; 1993 Dec; 3(3):163-8. PubMed ID: 8118397
[TBL] [Abstract][Full Text] [Related]
11. DNA damage, c-myc suppression and apoptosis induced by the novel topoisomerase II inhibitor, salvicine, in human breast cancer MCF-7 cells.
Lu HR; Meng LH; Huang M; Zhu H; Miao ZH; Ding J
Cancer Chemother Pharmacol; 2005 Mar; 55(3):286-94. PubMed ID: 15592835
[TBL] [Abstract][Full Text] [Related]
12. Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA-binding activity, and formation of Jun/Fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26.
Kim R; Beck WT
Cancer Res; 1994 Sep; 54(18):4958-66. PubMed ID: 8069863
[TBL] [Abstract][Full Text] [Related]
13. Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance.
Li L; Keating MJ; Plunkett W; Yang LY
Mol Pharmacol; 1997 Nov; 52(5):798-806. PubMed ID: 9351970
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase II cleavable complex formation within DNA loop domains.
Lambert JM; Fernandes DJ
Biochem Pharmacol; 2000 Jul; 60(1):101-9. PubMed ID: 10807951
[TBL] [Abstract][Full Text] [Related]
15. Analysis of 2-chloro-2'-deoxyadenosine incorporation into cellular DNA by quantitative polymerase chain reaction.
Yuh SH; Tibudan M; Hentosh P
Anal Biochem; 1998 Aug; 262(1):1-8. PubMed ID: 9735141
[TBL] [Abstract][Full Text] [Related]
16. Rapid polymerase chain reaction assay to detect variation in the extent of gene-specific damage between cisplatin- or VP-16-resistant and sensitive lung cancer cell lines.
Oshita F; Saijo N
Jpn J Cancer Res; 1994 Jul; 85(7):669-73. PubMed ID: 8071107
[TBL] [Abstract][Full Text] [Related]
17. [Molecular mechanism of cisplatin to enhance the ability of TRAIL in reversing multidrug resistance in gastric cancer cells].
Zhu X; Zhang K; Wang Q; Chen S; Gou Y; Cui Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):404-11. PubMed ID: 26463141
[TBL] [Abstract][Full Text] [Related]
18. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA.
Woynarowski JM; Chapman WG; Napier C; Herzig MC; Juniewicz P
Mol Pharmacol; 1998 Nov; 54(5):770-7. PubMed ID: 9804612
[TBL] [Abstract][Full Text] [Related]
19. Induction of apoptosis by dexrazoxane (ICRF-187) through caspases in the absence of c-jun expression and c-Jun NH2-terminal kinase 1 (JNK1) activation in VM-26-resistant CEM cells.
Khélifa T; Beck WT
Biochem Pharmacol; 1999 Oct; 58(8):1247-57. PubMed ID: 10487526
[TBL] [Abstract][Full Text] [Related]
20. DNA damage by anti-cancer agents resolved at the nucleotide level of a single copy gene: evidence for a novel binding site for cisplatin in cells.
Grimaldi KA; McAdam SR; Souhami RL; Hartley JA
Nucleic Acids Res; 1994 Jun; 22(12):2311-7. PubMed ID: 8036159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
